secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2025-06-13T23:59:59+00:00
Accession:  0001104659-25-059464
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Iovance CFO Jean-Marc Bellemin resigns effective July 10, 2025
--------------------------------------------------------------

- Jean-Marc Bellemin, CFO and principal financial & accounting officer, resigns effective July 10, 2025.
- No replacement named; company states departure is to pursue other opportunities.
- Frederick G. Vogt serves as Interim CEO and President; CFO role remains unfilled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465925059464/0001104659-25-059464-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465925059464/tm2517988d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-059464

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer